Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) were down 2.2% on Wednesday . The stock traded as low as $16.53 and last traded at $16.61. Approximately 24,805 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 571,121 shares. The stock had previously closed at $16.98.
Analysts Set New Price Targets
Several research analysts have issued reports on MESO shares. Maxim Group upgraded shares of Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. Piper Sandler increased their price objective on shares of Mesoblast from $11.00 to $15.00 and gave the company an "overweight" rating in a research note on Thursday, December 19th. Finally, Jefferies Financial Group cut Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Mesoblast currently has an average rating of "Hold" and a consensus target price of $13.50.
Read Our Latest Stock Analysis on MESO
Mesoblast Trading Up 0.7 %
The business's fifty day moving average price is $13.76 and its two-hundred day moving average price is $9.69. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.
Institutional Trading of Mesoblast
A number of institutional investors have recently made changes to their positions in MESO. GAMMA Investing LLC raised its stake in Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock valued at $133,000 after buying an additional 1,213 shares during the last quarter. Perkins Coie Trust Co increased its holdings in shares of Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock valued at $94,000 after acquiring an additional 1,500 shares in the last quarter. Signaturefd LLC raised its position in shares of Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company's stock valued at $45,000 after purchasing an additional 3,099 shares during the last quarter. Lazari Capital Management Inc. boosted its stake in Mesoblast by 6.6% in the 2nd quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company's stock worth $364,000 after purchasing an additional 3,300 shares in the last quarter. Finally, Rathbones Group PLC purchased a new stake in Mesoblast during the 2nd quarter worth approximately $95,000. Institutional investors and hedge funds own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
